Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 EUR | 0.00% | 0.00% | +3.73% |
04-22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
04-11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
Sales 2024 * | 78.6M 84.18M 6.72B | Sales 2025 * | 82.25M 88.09M 7.03B | Capitalization | 35.88M 38.42M 3.07B |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.07M -85.44M | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 0.59 x |
Net Debt 2024 * | 10.6M 11.35M 906M | Net Debt 2025 * | 6.9M 7.39M 590M | EV / Sales 2025 * | 0.52 x |
P/E ratio 2024 * |
-25
x | P/E ratio 2025 * |
100
x | Employees | 1,071 |
Yield 2024 * |
2.2% | Yield 2025 * |
3.8% | Free-Float | 100% |
Current month | +5.93% | ||
1 month | +5.93% | ||
3 months | -5.30% | ||
6 months | -8.76% | ||
Current year | +3.73% |
Managers | Title | Age | Since |
---|---|---|---|
Kimmo Herranen
CEO | Chief Executive Officer | 51 | 31/12/04 |
Kalle Lehtonen
DFI | Director of Finance/CFO | 50 | 31/07/23 |
Director/Board Member | 54 | 31/12/93 |
Members of the board | Title | Age | Since |
---|---|---|---|
Risto Koivula
BRD | Director/Board Member | 56 | 15/08/21 |
Chairman | 58 | 30/06/18 | |
Director/Board Member | 56 | 30/04/22 |
Date | Price | Change | Volume |
---|---|---|---|
25/04/24 | 2.5 | 0.00% | 163 |
24/04/24 | 2.5 | 0.00% | 50 |
23/04/24 | 2.5 | 0.00% | 1,547 |
22/04/24 | 2.5 | 0.00% | 466 |
Delayed Quote Nasdaq Helsinki, April 25, 2024 at 09:33 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.73% | 38.3M | |
-2.87% | 6.49B | |
-.--% | 62.2M | |
-19.85% | 59.1M |
- Stock Market
- Equities
- ADMIN Stock